<?xml version='1.0' encoding='utf-8'?>
<document id="26884555"><sentence text="Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial."><entity charOffset="77-87" id="DDI-PubMed.26884555.s1.e0" text="Irinotecan" /><entity charOffset="92-104" id="DDI-PubMed.26884555.s1.e1" text="Temozolomide" /><pair ddi="false" e1="DDI-PubMed.26884555.s1.e0" e2="DDI-PubMed.26884555.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26884555.s1.e0" e2="DDI-PubMed.26884555.s1.e1" /></sentence><sentence text="Alisertib is an oral Aurora A kinase inhibitor with preclinical activity in neuroblastoma" /><sentence text=" Irinotecan and temozolomide have activity in patients with advanced neuroblastoma"><entity charOffset="1-11" id="DDI-PubMed.26884555.s3.e0" text="Irinotecan" /><entity charOffset="16-28" id="DDI-PubMed.26884555.s3.e1" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.26884555.s3.e0" e2="DDI-PubMed.26884555.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26884555.s3.e0" e2="DDI-PubMed.26884555.s3.e1" /></sentence><sentence text=" The goal of this phase I study was to determine the maximum tolerated dose (MTD) of alisertib with irinotecan and temozolomide in this population"><entity charOffset="100-110" id="DDI-PubMed.26884555.s4.e0" text="irinotecan" /><entity charOffset="115-127" id="DDI-PubMed.26884555.s4.e1" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.26884555.s4.e0" e2="DDI-PubMed.26884555.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26884555.s4.e0" e2="DDI-PubMed.26884555.s4.e1" /></sentence><sentence text="" /><sentence text="Patients age 1 to 30 years with relapsed or refractory neuroblastoma were eligible" /><sentence text=" Patients received alisertib tablets at dose levels of 45, 60, and 80 mg/m(2) per day on days 1 to 7 along with irinotecan 50 mg/m(2) intravenously and temozolomide 100 mg/m(2) orally on days 1 to 5"><entity charOffset="19-28" id="DDI-PubMed.26884555.s7.e0" text="alisertib" /><entity charOffset="112-122" id="DDI-PubMed.26884555.s7.e1" text="irinotecan" /><entity charOffset="152-164" id="DDI-PubMed.26884555.s7.e2" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.26884555.s7.e0" e2="DDI-PubMed.26884555.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26884555.s7.e0" e2="DDI-PubMed.26884555.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26884555.s7.e0" e2="DDI-PubMed.26884555.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26884555.s7.e1" e2="DDI-PubMed.26884555.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26884555.s7.e1" e2="DDI-PubMed.26884555.s7.e2" /></sentence><sentence text=" Dose escalation of alisertib followed the rolling six design" /><sentence text=" Samples for pharmacokinetic and pharmacogenomic testing were obtained" /><sentence text="" /><sentence text="Twenty-three patients enrolled, and 22 were eligible and evaluable for dose escalation" /><sentence text=" A total of 244 courses were administered" /><sentence text=" The MTD for alisertib was 60 mg/m(2), with mandatory myeloid growth factor support and cephalosporin prophylaxis for diarrhea"><entity charOffset="88-101" id="DDI-PubMed.26884555.s13.e0" text="cephalosporin" /></sentence><sentence text=" Thrombocytopenia and neutropenia of any grade were seen in the majority of courses (84% and 69%, respectively)" /><sentence text=" Diarrhea in 55% of courses and nausea in 54% of courses were the most common nonhematologic toxicities" /><sentence text=" The overall response rate was 31" /><sentence text="8%, with a 50% response rate observed at the MTD" /><sentence text=" The median number of courses per patient was eight (range, two to 32)" /><sentence text=" Progression-free survival rate at 2 years was 52" /><sentence text="4%" /><sentence text=" Pharmacokinetic testing did not show evidence of drug-drug interaction between irinotecan and alisertib"><entity charOffset="80-90" id="DDI-PubMed.26884555.s21.e0" text="irinotecan" /><entity charOffset="95-104" id="DDI-PubMed.26884555.s21.e1" text="alisertib" /><pair ddi="false" e1="DDI-PubMed.26884555.s21.e0" e2="DDI-PubMed.26884555.s21.e0" /><pair ddi="false" e1="DDI-PubMed.26884555.s21.e0" e2="DDI-PubMed.26884555.s21.e1" /></sentence><sentence text="" /><sentence text="Alisertib 60 mg/m(2) per dose for 7 days is tolerable with a standard irinotecan and temozolomide backbone and has promising response and progression-free survival rates"><entity charOffset="70-80" id="DDI-PubMed.26884555.s23.e0" text="irinotecan" /><entity charOffset="85-97" id="DDI-PubMed.26884555.s23.e1" text="temozolomide" /><pair ddi="false" e1="DDI-PubMed.26884555.s23.e0" e2="DDI-PubMed.26884555.s23.e0" /><pair ddi="false" e1="DDI-PubMed.26884555.s23.e0" e2="DDI-PubMed.26884555.s23.e1" /></sentence><sentence text=" A phase II trial of this regimen is ongoing" /><sentence text="" /></document>